Quantcast
Viewing all articles
Browse latest Browse all 3128

Eisai terminates Phase 3 trial of Dravet drug lorcaserin

Eisai has stopped the Phase 3 clinical development of an adjunctive treatment for Dravet syndrome, a spokesperson confirmed to Endpoints News on Friday afternoon. The Tokyo drugmaker terminated the late-stage

Viewing all articles
Browse latest Browse all 3128

Trending Articles